Almirall transfers rights to respiratory business to AstraZeneca

3 November 2014

Spanish pharma company Almirall (ALM: MC) has transferred the rights to its respiratory franchise to Anglo-Swedish drug major AstraZeneca (LSE: AZN). This gives AstraZeneca ownership of the rights for the development and commercialization of Almirall’s proprietary respiratory businesses, which includes rights and revenues from Almirall’s existing partnerships, as well as its pipeline of investigational novel therapies.

As previously announced (The Pharma Letter July 30), the franchise includes Eklira (aclidinium), and Duaklir Genuair (aclidinium/formoterol) which has received a positive opinion from the CHMP in the EU and is being developed in the USA.

AstraZeneca will access all on-market revenues, contributing to the company’s return to growth, but says it will have no impact on the company’s financial guidance for 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK